Center for Clinical & Epidemiological Research, Internal Medicine Department, Hospital Universitário, Universidade de Sao Paulo, Brazil.
Department of Biochemistry & Immunology, Universidade Federal de Minas Gerais, Brazil.
Biomark Med. 2018 Nov;12(11):1219-1229. doi: 10.2217/bmm-2018-0110. Epub 2018 Nov 20.
We aimed to analyze the influence of myeloperoxidase (MPO) activity on mortality in the Acute Coronary Syndrome Registry Strategy (ERICO) study.
MPO activity levels were evaluated in 342 patients. We performed survival analyses using Kaplan-Meier curves and Cox regression with respective hazard ratios, 95% CI, according to MPO tertiles distribution up to 7 years of follow-up.
Higher MPO activity levels were seen in men, smokers, diabetics and those who were taking aspirin. MPO activity levels were neither significant in relation to mortality nor to survival rates up to seven years.
We found no relationship between elevated levels of MPO activity post-acute coronary syndrome and mortality up to 7-years of follow-up in the ERICO study.
我们旨在分析髓过氧化物酶（MPO）活性对急性冠脉综合征注册策略（ERICO）研究死亡率的影响。
在 342 例患者中评估 MPO 活性水平。我们使用生存分析，通过 Kaplan-Meier 曲线和 Cox 回归，根据 MPO 三分位分布，对 7 年的随访结果进行相应的危险比（HR）、95%置信区间（CI）分析。
男性、吸烟者、糖尿病患者和服用阿司匹林的患者 MPO 活性水平较高。MPO 活性水平与死亡率或 7 年的生存率均无显著关系。
在 ERICO 研究中，我们发现急性冠脉综合征后 MPO 活性水平升高与 7 年的随访死亡率之间没有关系。
